TAFERO EM

About

TAFERO EM is a fixed-dose combination medication containing Tenofovir Alafenamide (TAF) and Emtricitabine (FTC), both nucleoside reverse transcriptase inhibitors (NRTIs). This combination is primarily used for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 35 kg. It is also indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents. TAF and FTC work by inhibiting the activity of HIV reverse transcriptase, an enzyme crucial for the virus to replicate, thereby reducing the viral load and increasing CD4+ cell counts.

Compared to older tenofovir formulations, Tenofovir Alafenamide (TAF) offers improved renal and bone safety profiles while maintaining potent antiviral efficacy. This makes TAFERO EM a preferred option for many patients, including those with pre-existing renal or bone health concerns. Adherence to the prescribed regimen is critical for treatment success and preventing the development of drug resistance.

Uses

• Treatment of HIV-1 infection
• Pre-exposure prophylaxis (PrEP) for HIV-1
• Chronic hepatitis B (TAF component, off-label in combination)
• Post-exposure prophylaxis (PEP) for HIV (part of regimen)

Directions For Use

Take orally once daily with or without food. Adhere strictly to the prescribed regimen to ensure optimal efficacy and prevent resistance.

Benefits

• Highly effective against HIV-1 infection
• Lower risk of kidney and bone toxicity compared to TDF
• Convenient once-daily dosing regimen
• Effective for HIV-1 pre-exposure prophylaxis (PrEP)
• Generally well-tolerated by patients
• Part of recommended first-line HIV treatment regimens

Side Effects

• Nausea
• Diarrhea
• Headache
• Fatigue
• Abdominal pain
• Dizziness
• Rash
• Weight gain
• Lactic acidosis (rare)
• Renal impairment (less common)
• Bone mineral density decrease (less common)
• Insomnia

Safety Measures

• Alcohol - Generally safe, but excessive alcohol consumption can worsen liver health, which is a particular concern in HIV-infected individuals.
• Pregnancy - Generally considered safe for use during pregnancy, but always consult a physician. The benefits of preventing HIV transmission often outweigh potential risks.
• Breastfeeding - Not recommended for HIV-positive mothers due to the risk of HIV transmission to the infant and potential drug effects.
• Liver - Use with caution in patients with severe hepatic impairment. Monitor liver function regularly, especially in patients co-infected with hepatitis B or C.
• Kidney - Dose adjustment is not typically needed for mild to moderate renal impairment. Avoid use in severe renal impairment (CrCl < 15 mL/min) unless on hemodialysis.
• Lung - No specific lung-related precautions. Monitor for opportunistic infections common in HIV-infected individuals.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.